GlaxoSmithKline will cut 320 jobs, none in Philadelphia or the U.S.

Emma Walmsley is the new CEO of GlaxoSmithKline.  She will succeed Andrew Witty who will retire in March.   Walmsley, 47, is currently the head of GSK Consumer Healthcare. Courtesy:  GlaxoSmithKline

GlaxoSmithKline said Wednesday it will sell its Horlicks drinks brand in the U.K., close a manufacturing site in Slough, England, and cut about 320 manufacturing jobs there. None of the changes will impact U.S. employment or sites, including Philadelphia, a spokeswoman said.

GSK employs 5,000 in the area at the Navy Yard and in Montgomery County in Upper Providence and Upper Merion.

The changes are the first since GSK’s new chief executive officer Emma Walmsley took the helm on April 1. Among the changes, GSK will sell its Maxi Nutrition brand in the U.K., outsource some manufacturing activities, and explore the sale of “some other smaller noncore nutrition brands.”

Glaxo said it is looking at selling its cephalosporins antibiotics business and sites where the products are made. GSK said it will continue to manufacture other antibiotics, including Augmentin, and will continue to do research on new antibiotics.

Glaxo also scrapped plans to build a new biologics plant in Ulverston in northern England because it no longer needs the additional capacity.

“None of the announcements made today have resulted from the U.K’s decision to leave the European Union,” the company said.

The changes will result in 320 job losses in the U.K. over the next four years, said GSK, based in Brentford near London.